Lecture by Professor John Todd, Director, JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research.
Genetics: define the genetic basis of the common autoimmune disease type 1 diabetes by fine-mapping disease-associated causal variants and haplotypes, identify their target genes, and investigate the regulation of these genes before and after cell activation/differentiation.
Phenotypes and mechanisms: identify aberrant cellular interactions and pathways caused by susceptibility genes that mediate a loss of immune tolerance to insulin-producing beta cells culminating in their destruction. These will provide potential targets for therapeutic intervention, as demonstrated by our work in the IL-2 pathway.
Experimental medicine: complete our mechanistic investigations of the effects of IL-2 administration in patients, as a prelude to testing the efficacy of ultra-low dose IL-2 in the preservation of C-peptide and beta-cell function. Investigate using the same mechanistic approach and depending on our emerging knowledge, another potential therapeutic.
Further information is at www.cimr.cam.ac.uk/investigators/todd.
The lecture is part of the Wellcome Trust Centre for Human Genetics' high-profile seminar series.